As a result, targeting PD-L1/PD-1 axis has become an intriguing immunotherapeutic strategy and has proved its clinical value in a variety of human cancers, such as melanoma [10, 11], non-small-cell lung cancer [12], hepatocellular carcinoma [13], gastric cancer [14], and etc. Here, CD274 is linked to cancer.